Spinraza (nusinersen) is a revolutionary treatment for spinal muscular atrophy (SMA), significantly improving patient survival rates globally. However, treatment costs vary greatly: patients in China benefit from subsidized access after successful price negotiations, while Australians also see affordable treatment through public funding. In stark contrast, U.S. patients face exorbitant prices influenced by insurance structures, making access highly variable. SMA, a severe inherited condition caused by SMN1 gene mutations, once lacked effective treatments until genetic therapies emerged. As healthcare systems adapt to these breakthroughs, a global conversation is underway about who should bear the financial burden of these innovations.